Use your device's search function to find a specific disease or funding source.
National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new funding opportunity for improving patient care and outcomes in Stage III, Stage IV and recurrent epithelial ovarian cancer (EOC). The intent of this RFP is to encourage investigators at NCCN Member Institutions to submit letters of intent (LOIs) describing concepts for developing, implementing, and evaluating initiatives to improve patient outcomes in Stages III/IV and recurrent EOC. Studies aimed at enhancing the quality of multiple aspects of patient interaction and management throughout the clinical care continuum will be eligible. Special consideration will be given to “outside the box” innovative projects, with a special focus on optimizing testing and effectiveness of new healthcare-related paradigms.
Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program.
Application Deadline: August 30, 2019, by 5:00 PM
- Refining treatment of metastatic breast cancer
- Early detection of metastatic breast cancer
Defense Health Program - Department of Defense Melanoma Research Program Funding Opportunities for Fiscal Year 2019 (FY19)
The FY19 Defense Appropriation provides $10 million (M) to the Department of Defense (DoD) Melanoma Research Program (MRP) to support innovative, high-impact melanoma research.
FY19 MRP Program Announcements and General Application Instructions for the following award mechanism is posted on the Grants.gov website.
The FY19 MRP Focus Areas are listed below:
• Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
• Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
• Therapeutic Prevention
• Minimal Residual Disease
• Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)
The MRP challenges the research community to redefine the concept of prevention and has issued a FY19 MRP Challenge Statement that should be considered when responding to the FY19 MRP Focus Areas and funding opportunities.
Investigators at or above postdoctoral fellow (or equivalent)
• Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in melanoma.
• Emphasis is on Innovation.
• Preliminary data is strongly discouraged.
• Clinical trials are not allowed.
• Blinded review.
• The maximum allowable funding for the entire period of performance is $75,000 in direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• The maximum period of performance is 1 year.
LOI Deadline: October 2, 2019; Application Deadline: October 23, 2019
The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process.
The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants.
Current opportunities are listed below.